Q1 Earnings Forecast for ODTX Issued By HC Wainwright

Odyssey Therapeutics, Inc. (NASDAQ:ODTX) – Stock analysts at HC Wainwright issued their Q1 2027 EPS estimates for Odyssey Therapeutics in a research note issued on Friday, November 6th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings per share of ($1.27) for the quarter. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Odyssey Therapeutics’ current full-year earnings is ($6.18) per share. HC Wainwright also issued estimates for Odyssey Therapeutics’ Q2 2027 earnings at ($1.29) EPS, Q3 2027 earnings at ($1.29) EPS and Q4 2027 earnings at ($1.28) EPS.

ODTX has been the subject of several other reports. UBS Group began coverage on shares of Odyssey Therapeutics in a research note on Monday, October 12th. They set a “buy” rating and a $27.00 target price for the company. Raymond James Financial initiated coverage on shares of Odyssey Therapeutics in a research note on Thursday, October 8th. They issued an “outperform” rating and a $42.00 price target on the stock. JPMorgan Chase & Co. boosted their price target on shares of Odyssey Therapeutics from $26.00 to $29.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Finally, Weiss Ratings assumed coverage on shares of Odyssey Therapeutics in a report on Tuesday, August 11th. They set a “sell (d+)” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $34.67.

Odyssey Therapeutics Trading Up 4.4%

ODTX stock opened at $20.00 on Monday. The stock has a fifty day moving average of $20.98. Odyssey Therapeutics has a one year low of $15.10 and a one year high of $29.05.

Institutional Trading of Odyssey Therapeutics

Large investors have recently added to or reduced their stakes in the company. Aberdeen Group plc raised its holdings in shares of Odyssey Therapeutics by 4.7% during the 3rd quarter. Aberdeen Group plc now owns 172,771 shares of the company’s stock worth $3,839,000 after acquiring an additional 7,771 shares in the last quarter. Russell Investments Group Ltd. purchased a new position in shares of Odyssey Therapeutics in the third quarter valued at $28,000. State Street Corp purchased a new position in shares of Odyssey Therapeutics in the second quarter valued at $1,477,000. The Manufacturers Life Insurance Company purchased a new position in shares of Odyssey Therapeutics in the second quarter valued at $601,000. Finally, Citadel Advisors LLC bought a new stake in Odyssey Therapeutics in the second quarter worth $4,162,000.

Odyssey Therapeutics News Summary

Here are the key news stories impacting Odyssey Therapeutics this week:

• Positive Sentiment: Odyssey announced a publication highlighting the differentiated therapeutic potential of TNFR2 agonism, which may support investor interest in its drug-development pipeline. Article: Odyssey Therapeutics Announces Publication Highlighting Differentiated Therapeutic Potential of TNFR2 Agonism
• Positive Sentiment: HC Wainwright reiterated a Buy rating and $40 price target, well above the recent trading level. Its forecasts anticipate narrowing annual losses after 2026, although the company is still expected to remain unprofitable through 2030. Odyssey Therapeutics analyst coverage
• Neutral Sentiment: A report listed short interest at zero shares and a days-to-cover ratio of zero, which indicates no reported short position to drive a short squeeze. This conflicts with the report’s description of a “large increase,” so the short-interest data may be unreliable.
• Negative Sentiment: HC Wainwright’s estimates still project substantial losses, including an estimated loss of $6.20 per share for 2026, underscoring Odyssey’s ongoing development-stage risks.

About Odyssey Therapeutics

Odyssey Therapeutics is a biotechnology company focused on discovering and developing medicines for inflammatory and autoimmune diseases. Its research centers on the immune system and biological pathways that may be targeted to address these conditions. Founded in 2021, the company uses drug-discovery capabilities to identify and advance potential therapies. Its business is research and development rather than the sale of marketed medicines. Odyssey is based in the United States. As a research-focused biotechnology company, its activities are centered on developing potential treatments rather than serving patients through a broad commercial product operation.